Trial · NCT05194839

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

NCT05194839, Phase 2, Terminated, Aristea Therapeutics, Inc.; results first posted 2023-06-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP). Trials, record NCT05194839. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05194839

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
NCT number: NCT05194839
Status: Terminated
Phases: Phase 2
Enrollment: 79 participants, actual
Lead sponsor: Aristea Therapeutics, Inc.
Conditions: Palmoplantar Pustulosis
Interventions: RIST4721, Placebo
First posted: 2022-01-18
Last updated: 2023-06-29
Results first posted: 2023-06-29

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Proportion of Subjects Achieving a 50% Reduction in PPPASI Score	Baseline to Week 12	In the Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI), the left palm, right palm, left foot, and right foot are assessed based on 3 target symptoms: erythema, desquamation (scaling), and pustules, as seen on the day of the examination. The severity of each sign is assessed using a 5-point scale (0 = not present, 1 = slight, 3 = moderate, 4 = severe, 5 = very severe). The affected area within a given anatomic site (left palm, right palm, left foot, and right foot) is estimated as a percentage of the total area of that anatomic site and assigned a numerical value according to the degree of PPP involvement (0 = no involvement, 2 = 10 to less than 30% involvement, 3 = 30 to less than 50% involvement, 4 = 50 to less than 70% involvement, 5 = 70 to less than 90% involvement, 6 = 90 to less than 100% involvement). PPPASI score for palms and soles is obtained using a formula and can vary from 0 (absence of disease) to 72 (most severe disease).
Secondary	Absolute Change From Baseline in PPPGA	Baseline to Week 12
Secondary	Absolute Change From Baseline in PPPASI	Baseline to Week 12

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Proportion of Subjects Achieving a 50% Reduction in PPPASI Score	Baseline to Week 12	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Absolute Change From Baseline in PPPGA	Baseline to Week 12
SECONDARY	Absolute Change From Baseline in PPPASI	Baseline to Week 12

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Proportion of Subjects Achieving a 50% Reduction in PPPASI Score	RIST4721 400 mg	6	Participants
Proportion of Subjects Achieving a 50% Reduction in PPPASI Score	RIST4721 200 mg	3	Participants
Proportion of Subjects Achieving a 50% Reduction in PPPASI Score	Placebo	5	Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	RIST4721 400 mg	27
Overall Study	STARTED	RIST4721 200 mg	26
Overall Study	STARTED	Placebo	26
Overall Study	COMPLETED	RIST4721 400 mg	12
Overall Study	COMPLETED	RIST4721 200 mg	13
Overall Study	COMPLETED	Placebo	12
Overall Study	NOT COMPLETED	RIST4721 400 mg	15
Overall Study	NOT COMPLETED	RIST4721 200 mg	13
Overall Study	NOT COMPLETED	Placebo	14

Source ClinicalTrials.gov

Adverse events204

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nasopharyngitis	Infections and infestations	RIST4721 400 mg	1	27
other	Nasopharyngitis	Infections and infestations	RIST4721 200 mg	3	26
other	Nasopharyngitis	Infections and infestations	Placebo	4	26
other	Urinary Tract Infection	Infections and infestations	RIST4721 400 mg	1	27
other	Urinary Tract Infection	Infections and infestations	RIST4721 200 mg	1	26
other	Urinary Tract Infection	Infections and infestations	Placebo	1	26
other	Covid-19	Infections and infestations	RIST4721 400 mg	1	27
other	Covid-19	Infections and infestations	RIST4721 200 mg	0	26
other	Covid-19	Infections and infestations	Placebo	1	26
other	Upper respiratory tract infection	Infections and infestations	RIST4721 400 mg	1	27

1 to 10 of 204Source ClinicalTrials.gov

See all 204 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	RIST4721 400 mg	0	27
Total, all-cause mortality	RIST4721 200 mg	0	26
Total, all-cause mortality	Placebo	0	26
Total, other adverse events	RIST4721 400 mg	18	27
Total, other adverse events	RIST4721 200 mg	17	26
Total, other adverse events	Placebo	18	26
Total, serious adverse events	RIST4721 400 mg	0	27
Total, serious adverse events	RIST4721 200 mg	1	26
Total, serious adverse events	Placebo	0	26

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05194839

GET https://conductscience.org/api/trials/v1/NCT05194839/events?page=2

API reference For AI assistants